drugset / Trial / NCT02052648
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
In this study, investigators will conduct a phase I/II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly diagnosed glioblastoma patients with radiation and temozolomide, or in combination with vaccine therapies.
Timeline
- Start
- 2014-03
- Primary completion
- 2018-04-18
- Completion
- 2019-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Indoximod | Small molecule | 600 mg | Oral |
| Subject | Indoximod | Small molecule | 1200 mg | Oral |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |